0001144204-18-019057.txt : 20180403
0001144204-18-019057.hdr.sgml : 20180403
20180403192653
ACCESSION NUMBER: 0001144204-18-019057
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180331
FILED AS OF DATE: 20180403
DATE AS OF CHANGE: 20180403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AUBERTON-HERVE ANDRE-JACQUES
CENTRAL INDEX KEY: 0001730329
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-54717
FILM NUMBER: 18735421
MAIL ADDRESS:
STREET 1: 18 CHEMIN DE LA VIERGE NOIRE
CITY: LA TRONCHE
STATE: I0
ZIP: 38700
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bionik Laboratories Corp.
CENTRAL INDEX KEY: 0001508381
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 271340346
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 483 BAY STREET
STREET 2: N105
CITY: TORONTO
STATE: A6
ZIP: M5G2C9
BUSINESS PHONE: 1.416.640.7887
MAIL ADDRESS:
STREET 1: 483 BAY STREET
STREET 2: N105
CITY: TORONTO
STATE: A6
ZIP: M5G2C9
FORMER COMPANY:
FORMER CONFORMED NAME: Drywave Technologies, Inc.
DATE OF NAME CHANGE: 20130814
FORMER COMPANY:
FORMER CONFORMED NAME: Strategic Dental Management Corp.
DATE OF NAME CHANGE: 20101220
4
1
tv490253_4.xml
OWNERSHIP DOCUMENT
X0306
4
2018-03-31
0
0001508381
Bionik Laboratories Corp.
BNKL
0001730329
AUBERTON-HERVE ANDRE-JACQUES
C/O BIONIK LABORATORIES CORP.
483 BAY STREET, N105
TORONTO
A6
M5G2C9
ONTARIO, CANADA
1
0
0
0
Common Stock
2018-03-31
4
C
0
12114710
0.0625
A
12679436
I
Shares held through Star SCI
Common Stock
2018-03-31
4
C
0
564726
0.0625
A
12679436
I
Shares held through 4A Consulting and Engineering
Warrant
0.0625
2017-08-14
4
A
0
1600640
0
A
2018-03-31
2022-08-14
Common Stock
1600640
1600640
I
Warrants held through held through Star SCI
On March 31, 2018, an aggregate amount of $821,850 in convertible promissory notes converted in accordance with their terms into (i) 12,114,710 shares of the Issuer's common stock, and (ii) 1,040,152 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance.
On March 31, 2018, an aggregate amount of $100,200 in convertible promissory notes converted in accordance with their terms into (i) 564,726 shares of the Issuer's common stock, and (ii) 1,039,115 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance.
As of the transaction date, the number of shares of common stock underlying warrants and the exercise price were not yet determinable. Such number of shares and exercise price were each determined on March 31, 2018.
/s/ Andre-Jacques Auberton-Herve
2018-04-03